Molmir

What Molmir does

Molmir Inc. (モルミル株式会社) is a Japanese biotech startup founded in 2022 as a triple-academic spinout from Nara Medical University, the National Institute of Advanced Industrial Science and Technology (AIST), and Tokushima University, headquartered in Kashihara City, Nara Prefecture. The company operates a B2B drug discovery platform built on three integrated technologies: CHEmir (ケムミル), a patented AI-powered analytical chemistry technology derived from AIST's chemical-tongue method for stratified analysis of protein aggregation and dispersion; MAGmir (マグミル), an NMR-based analytical technology that evaluates molecular dynamics and drug-target interactions at atomic resolution under near-physiological conditions without requiring crystallization; and TEAmir (チームミル), a curated network of 15 scientific advisors from 13 academic and clinical institutions. Together these capabilities enable analysis of dynamic molecular structures — particularly those involved in protein phase separation and aggregation — that conventional technologies like X-ray crystallography cannot adequately characterize.

Molmir targets pharmaceutical and biotechnology companies as well as academic research institutions engaged in drug discovery for neurodegenerative diseases (ALS, Parkinson's, Alzheimer's), hematology (Acquired von Willebrand Syndrome), and other conditions where molecular dynamics are central to pathogenesis. The company pursues a professional services and collaborative R&D revenue model, delivering molecular dynamics analysis, drug discovery screening, and joint research programs. Strategic partnerships include OrganoTherapeutics (Luxembourg, Parkinson's organoid models), Veneno Technologies (peptide discovery platform integration), and ongoing collaborations with Nara Medical University, AIST, Tokushima University, and Tohoku University. The company is privately held with 1-10 employees, has raised pre-seed, seed, and Series A funding (April 2026, ~$1.88M) from Japanese deep-tech investors led by UntroD Capital Japan and Mitsubishi UFJ Capital, and has secured multiple R&D grants alongside participation in JETRO, METI, and Ministry of Health accelerator programs targeting UK and US market entry.

Name

Molmir

Legal name

molmir株式会社 (molmir, Inc.)

Website

https://molmir.co.jp

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Molmir is a Japanese biotech startup (founded 2022) that operates a drug discovery platform combining patented AI-powered chemistry analysis (CHEmir) and NMR-based molecular dynamics analytics (MAGmir) with a scientific advisor network (TEAmir), serving pharmaceutical companies and academic institutions developing treatments for neurodegenerative and other intractable diseases.

Ownership category

akta.pro rank

Product category

Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• Drug discovery platform
• Molecular dynamics analysis
• Neurodegenerative therapeutics
• Protein aggregation screening
• Biotech research services

Headquarters

HQ city

Nara

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Drug Discovery Platform Services: Molmir provides molecular dynamics evaluation services to pharmaceutical and biotech companies engaged in drug development. Services include CHEmir-based screening and MAGmir-based analysis for evaluating therapeutic targets and drug candidates. Revenue is generated through service contracts with pharmaceutical partners, academic collaborations, and potentially out-licensing of developed therapeutics.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Molmir is a biotech company that operates a molecular dynamics drug discovery platform providing analytical chemistry and NMR-based evaluation services to pharmaceutical and biotech firms. The platform combines three proprietary technologies—CHEmir (AI-powered analytical chemistry), MAGmir (NMR-based analytics), and TEAmir (scientific advisor network)—to analyze dynamic molecular structures, enabling drug discovery for previously 'undruggable' targets including ALS, Parkinson's disease, and Alzheimer's disease.

Product overview

Molmir operates a unified drug discovery platform built on three integrated core technologies: CHEmir (a patented AI-powered analytical chemistry technology based on chemical-tongue methods for evaluating protein assembly/dispersion through stratified molecular analysis), MAGmir (an NMR-based analytical technology that evaluates molecular movements and interactions at atomic resolution), and TEAmir (a network of 15 scientific advisors from 13 institutions including clinicians). The platform targets dynamic molecular structures considered 'undruggable' by conventional approaches, supports modality-agnostic drug discovery (small molecules, peptides, antibodies, nucleic acids), and enables analysis under near-physiological conditions without crystallization requirements. Molmir applies this platform to proprietary ALS drug discovery programs and supports academic-to-industrial translation of drug discovery seeds.

Differentiator

Problem solved

Functional benefit

Brands

• CHEmir (ケムミル): AI-powered analytical chemistry technology for patent-protected molecular dynamics detection
• MAGmir (マグミル)
• TEAmir (チームミル)

Products and services

• CHEmir (Chemir) A patented AI-powered analytical chemistry technology (chemical-tongue-based) that aggregates and analyzes various characteristics of molecules for stratified analysis, enabling efficient and comprehensive analysis of protein assembly and dispersion for large-scale drug discovery screening under near-physiological conditions.
• MAGmir (Magmir) An NMR (nuclear magnetic resonance)-based analytical technology that evaluates molecular movements and interactions with atomic-level resolution, capturing the dynamics of single molecules and evaluating interactions between target molecules and drug candidate substances under near-physiological conditions without requiring crystallization.
• Molecular Dynamics Drug Discovery Platform A comprehensive drug discovery platform addressing challenges across the entire drug discovery process, targeting dynamic molecular structures considered 'undruggable' by conventional approaches. Supports modality-agnostic drug discovery (small molecules, peptides, antibodies, nucleic acids) under near-physiological conditions without crystallization.
• ALS Drug Discovery Screening Program A proprietary drug discovery screening program for Amyotrophic Lateral Sclerosis (ALS) built on CHEmir and MAGmir technologies, providing tangible proof of the platform's practical applicability through ongoing drug discovery research targeting neurodegenerative diseases.

Quantifiable outcome

• ALS pathology-inhibiting factor discovered using MAGmir technology - published in Nature Communications 2025
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and supporting.

• National Institute of Advanced Industrial Science and Technology (AIST)coreStrategic or Co-development Partner · 24 February 2026Joint research partnership for developing CHEmir technology from AIST's chemical-tongue technology. The collaboration enabled molmir to develop and validate the CHEmir service for drug discovery screening applications. AIST is a Japanese national research organization.
• Nara Medical University (AVWS Research)coreStrategic or Co-development Partner · 12 December 2025Joint research project with Nara Medical University to develop novel targeted therapeutics and diagnostic technologies for Acquired von Willebrand Syndrome (AVWS). Led by Professor Masanori Matsumoto, a world-leading authority in AVWS research.
• Veneno Technologies CorporationcoreStrategic or Co-development Partner · 10 December 2025Strategic partnership for creating an 'academia-driven industrialization model' for drug discovery. Combines molmir's molecular dynamics evaluation technologies and TEAmir network with Veneno's DRP (Disulfide-Rich Peptide) drug discovery platform and PERISS method to accelerate academia-based drug development.
• OrganoTherapeutics SARLcoreStrategic or Co-development Partner · 27 June 2025Molmir and OrganoTherapeutics entered into R&D collaboration for developing novel therapies for Parkinson's disease. The partnership combines molmir's molecular dynamics analysis technologies (CHEmir, MAGmir) with OrganoTherapeutics' patient-specific 3D midbrain organoid models to accelerate drug discovery. OrganoTherapeutics is an academic-spinout biotech based in Luxembourg, led by CEO Jens Schwamborn from University of Luxembourg.
• Tokushima UniversitycoreStrategic or Co-development PartnerJoint research partnership with Professor Tomohide Saio's team for developing MAGmir technology using NMR-based molecular dynamics analysis. The collaboration enabled molmir to develop and validate the MAGmir service for therapeutic evaluation.
• Nara Medical UniversitycoreStrategic or Co-development PartnerLong-standing academic partnership including joint research on ALS and establishment of the Molecular Dynamics Drug Discovery Joint Research Course. Professor Kazuma Sugie leads collaboration focusing on neurodegenerative disease therapeutics. Molmir originated from this university.
• Nakanoshima Qross / Future Medical Promotion OrganizationsupportingImplementation/ SI/ Consulting PartnerSelected as startup for Nakanoshima Qross Drug Discovery and Practical Application Promotion Program supported by Ministry of Health, Labor and Welfare's Drug Discovery Cluster Campus Development Project. Provides access to drug discovery ecosystem support and resources.
• JETRO / Ministry of Economy, Trade and Industry (METI)supportingGTM or Marketing PartnerParticipated in J-StarX BioUK Launchpad program organized by JETRO and METI to develop business toward UK life science ecosystem. Program included pitching at Demo Day in London organized by MedCity to improve global recognition.
• Ministry of Health, Labour and Welfare (Direct Flight Program)supportingGTM or Marketing PartnerSelected for Ministry of Health's Medical Startups Global Acceleration Program 'Direct Flight' Philadelphia program as a venture aiming for global expansion. Provides knowledge, experience, and networks for overseas expansion to North America.
• Plug and Play JapansupportingGTM or Marketing PartnerSelected for Plug and Play Rising Biotech Challenge accelerator program for biotech research seeds and startups. Provides access to large corporate partnerships and innovation programs in 8 cities globally.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/molmir_inc
• LinkedInlinkedin.com/company/molmir

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molmir